Rochal Industries is structured around research into synthetic and naturally modified polymers that serve as substrates for human cell attachment, viability, and proliferation. Without the use of added growth factors, proteins, or cells (either autologous or allogeneic), this work facilitates development of unique burn and wound care products. The firm has extensive expertise in biomedical materials and devices involved in the creation, development, and manufacture of products pertaining to: Biomaterials antimicrobial materials for reduction of opportunistic pathogens and biofilms cell compatible substrates. Clinical Challenges wound re-epithelialization and closure necrotic tissue scar reduction and in the Evolving Fields regenerative medicine transdermal drug delivery. The particular focus of Rochal as a company is their extensive scientific, technical and clinical expertise in biomedical materials as related to the wound care and eye care industries. Areas of product application-interest also extent to diabetic ulcers, pressure ulcers, and venous ulcers - major health concerns, with roughly 2 % of the general population of the U.S. affected. Healing these wounds is critical to increasing the likelihood that the patient can recover from the underlying conditions while decreasing the risk of local and systemic infection, reducing risk of amputation, and improving overall quality of life.
